Advertisement
Australia markets close in 5 hours 25 minutes

  • ALL ORDS

    7,963.30
    +25.40 (+0.32%)
     

  • ASX 200

    7,709.20
    +25.70 (+0.33%)
     

  • AUD/USD

    0.6494
    +0.0005 (+0.08%)
     

  • OIL

    83.45
    +0.09 (+0.11%)
     

  • GOLD

    2,335.20
    -6.90 (-0.29%)
     

  • Bitcoin AUD

    102,742.37
    -294.70 (-0.29%)
     

  • CMC Crypto 200

    1,430.55
    +15.79 (+1.12%)
     

  • AUD/EUR

    0.6061
    +0.0004 (+0.07%)
     

  • AUD/NZD

    1.0926
    -0.0004 (-0.04%)
     

  • NZX 50

    11,848.49
    +45.21 (+0.38%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • NIKKEI 225

    38,278.33
    +726.17 (+1.93%)
     

Has ResMed (RMD) Outpaced Other Medical Stocks This Year?

Zacks Equity Research
·2-min read

Investors focused on the Medical space have likely heard of ResMed (RMD), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of RMD and the rest of the Medical group's stocks.

ResMed is a member of our Medical group, which includes 903 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. RMD is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for RMD's full-year earnings has moved 0.15% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

ADVERTISEMENT

Based on the latest available data, RMD has gained about 32.69% so far this year. Meanwhile, stocks in the Medical group have gained about 1.97% on average. This means that ResMed is outperforming the sector as a whole this year.

Looking more specifically, RMD belongs to the Medical - Products industry, a group that includes 81 individual stocks and currently sits at #159 in the Zacks Industry Rank. Stocks in this group have lost about 1.96% so far this year, so RMD is performing better this group in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on RMD as it attempts to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.